<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39366721</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2052-4439</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>04</Day></PubDate></JournalIssue><Title>BMJ open respiratory research</Title><ISOAbbreviation>BMJ Open Respir Res</ISOAbbreviation></Journal><ArticleTitle>Pulmonary fibrosis followed by severe pneumonia in patients with COVID-19 infection requiring mechanical ventilation: a prospective multicentre study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e002538</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjresp-2024-002538</ELocationID><Abstract><AbstractText Label="BACKGROUNDS" NlmCategory="BACKGROUND">The management of lung complications, especially fibrosis, after COVID-19 pneumonia, is an important issue in the COVID-19 post-pandemic era. We aimed to investigate risk factors for pulmonary fibrosis development in patients with severe COVID-19 pneumonia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Clinical and radiological data were prospectively collected from 64 patients who required mechanical ventilation due to COVID-19 pneumonia and were enrolled from eight hospitals in South Korea. Fibrotic changes on chest CT were evaluated by visual assessment, and extent of fibrosis (mixed disease score) was measured using automatic quantification system.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">64 patients were enrolled, and their mean age was 58.2 years (64.1% were males). On chest CT (median interval: 60 days [IQR; 41-78 days] from enrolment), 35 (54.7%) patients showed ≥3 fibrotic lesions. The most frequent fibrotic change was traction bronchiectasis (47 patients, 73.4 %). Median extent of fibrosis measured by automatic quantification was 10.6% (IQR, 3.8-40.7%). In a multivariable Cox proportional hazard model, which included nine variables with a p value of &lt;0.10 in an unadjusted analysis as well as age, sex and Body Mass Index, male sex (HR, 3.01; 95% CI, 1.27 to 7.11) and higher initial Sequential Organ Failure Assessment (SOFA) score (HR, 1.18; 95% CI, 1.02 to 1.37) were independently associated with pulmonary fibrosis (≥3 fibrotic lesions).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our data suggests that male gender and higher SOFA score at intensive care unit admission were associated with pulmonary fibrosis in patients with severe COVID-19 pneumonia requiring mechanical ventilation.</AbstractText><CopyrightInformation>© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Junghyun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6868-6534</Identifier><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University College of Medicine, Dongtan Sacred Heart Hospital, Hwaseong, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chae</LastName><ForeName>Ganghee</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Pulmonology, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Won-Young</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Chi-Ryang</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Suwon, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Young-Jae</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jinwoo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Jongno-gu, Seoul, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jegal</LastName><ForeName>Yangjin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Pulmonology, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joh</LastName><ForeName>Joon-Sung</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Medical Centre, Seoul, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Tae Yun</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Seoul Metropolitan Government Boramae Medical Center, Dongjak-gu, Seoul, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Jung Hwa</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Radiology, Soonchunhyang University Hospital, Yongsan-gu, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nam</LastName><ForeName>Bo Da</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Department of Radiology, Soonchunhyang University Hospital, Yongsan-gu, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Hee-Young</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Division of Allergy and Respiratory Diseases, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Jin Woo</ForeName><Initials>JW</Initials><Identifier Source="ORCID">0000-0001-5121-3522</Identifier><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Songpa-gu, Korea (the Republic of) jwsongasan@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open Respir Res</MedlineTA><NlmUniqueID>101638061</NlmUniqueID><ISSNLinking>2052-4439</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="Y">Respiration, Artificial</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011658" MajorTopicYN="Y">Pulmonary Fibrosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="Y">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Idiopathic Pulmonary Fibrosis</Keyword><Keyword MajorTopicYN="N">Pneumonia</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>7</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>7</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>20</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39366721</ArticleId><ArticleId IdType="pmc">PMC11481150</ArticleId><ArticleId IdType="doi">10.1136/bmjresp-2024-002538</ArticleId><ArticleId IdType="pii">11/1/e002538</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382:727–33. doi: 10.1056/NEJMoa2001017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Weekly epidemiological update on covid-19. 2022.  [30-Nov-2022]. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---30-november-2022 Available. Accessed.</Citation></Reference><Reference><Citation>Gao Y-D, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76:428–55. doi: 10.1111/all.14657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14657</ArticleId><ArticleId IdType="pubmed">33185910</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Q, Liu J, Liu Q, et al. Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-analysis. JAMA Netw Open . 2021;4:e2137257. doi: 10.1001/jamanetworkopen.2021.37257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.37257</ArticleId><ArticleId IdType="pmc">PMC8672238</ArticleId><ArticleId IdType="pubmed">34905008</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020;20:425–34. doi: 10.1016/S1473-3099(20)30086-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30086-4</ArticleId><ArticleId IdType="pmc">PMC7159053</ArticleId><ArticleId IdType="pubmed">32105637</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou J-N, Sun L, Wang B-R, et al. The characteristics and evolution of pulmonary fibrosis in COVID-19 patients as assessed by AI-assisted chest HRCT. PLoS One. 2021;16:e0248957. doi: 10.1371/journal.pone.0248957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0248957</ArticleId><ArticleId IdType="pmc">PMC7987145</ArticleId><ArticleId IdType="pubmed">33755708</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabahati M, Ebrahimpour S, Khaleghnejad Tabari R, et al. Post-COVID-19 pulmonary fibrosis and its predictive factors: a prospective study. Egypt J Radiol Nucl Med . 2021;52:1–7. doi: 10.1186/s43055-021-00632-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43055-021-00632-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernández-Plata R, Higuera-Iglesias A-L, Torres-Espíndola LM, et al. Risk of Pulmonary Fibrosis and Persistent Symptoms Post-COVID-19 in a Cohort of Outpatient Health Workers. Viruses. 2022;14:1843. doi: 10.3390/v14091843.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14091843</ArticleId><ArticleId IdType="pmc">PMC9504101</ArticleId><ArticleId IdType="pubmed">36146648</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon HY, Uh ST. Post-Coronavirus Disease 2019 Pulmonary Fibrosis: Wait or Needs Intervention. Tuberc Respir Dis (Seoul) 2022;85:320–31. doi: 10.4046/trd.2022.0053.</Citation><ArticleIdList><ArticleId IdType="doi">10.4046/trd.2022.0053</ArticleId><ArticleId IdType="pmc">PMC9537661</ArticleId><ArticleId IdType="pubmed">35722706</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran S, Ksajikian A, Overbey J, et al. Pathophysiology of Pulmonary Fibrosis in the Context of COVID-19 and Implications for Treatment: A Narrative Review. Cells. 2022;11:2489. doi: 10.3390/cells11162489.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11162489</ArticleId><ArticleId IdType="pmc">PMC9406710</ArticleId><ArticleId IdType="pubmed">36010566</ArticleId></ArticleIdList></Reference><Reference><Citation>Delpino MV, Quarleri J. SARS-CoV-2 Pathogenesis: Imbalance in the Renin-Angiotensin System Favors Lung Fibrosis. Front Cell Infect Microbiol. 2020;10:340. doi: 10.3389/fcimb.2020.00340.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2020.00340</ArticleId><ArticleId IdType="pmc">PMC7303284</ArticleId><ArticleId IdType="pubmed">32596170</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera-Benítez NE, Parotto M, Post M, et al. Mechanical stress induces lung fibrosis by epithelial-mesenchymal transition. Crit Care Med. 2012;40:510–7. doi: 10.1097/CCM.0b013e31822f09d7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31822f09d7</ArticleId><ArticleId IdType="pmc">PMC5061566</ArticleId><ArticleId IdType="pubmed">21926573</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasin R, Gomaa AAK, Ghazy T, et al. Predicting lung fibrosis in post-COVID-19 patients after discharge with follow-up chest CT findings. Egypt J Radiol Nucl Med . 2021;52:1–13. doi: 10.1186/s43055-021-00495-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43055-021-00495-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Shen C, Wang L, et al. Pulmonary fibrosis and its related factors in discharged patients with new corona virus pneumonia: a cohort study. Respir Res. 2021;22:203. doi: 10.1186/s12931-021-01798-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-021-01798-6</ArticleId><ArticleId IdType="pmc">PMC8267229</ArticleId><ArticleId IdType="pubmed">34243776</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet. 2021;397:220–32. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Naderi N, Rahimzadeh M. Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses. Virology (Auckl) 2022;566:106–13. doi: 10.1016/j.virol.2021.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2021.11.006</ArticleId><ArticleId IdType="pmc">PMC8642780</ArticleId><ArticleId IdType="pubmed">34896901</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Z-J, Xu J, Yin J-M, et al. Lower Circulating Interferon-Gamma Is a Risk Factor for Lung Fibrosis in COVID-19 Patients. Front Immunol. 2020;11:585647. doi: 10.3389/fimmu.2020.585647.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.585647</ArticleId><ArticleId IdType="pmc">PMC7550399</ArticleId><ArticleId IdType="pubmed">33133104</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Living guidance for clinical management of covid-19</Citation></Reference><Reference><Citation>Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–38. doi: 10.1183/09031936.05.00034805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.05.00034805</ArticleId><ArticleId IdType="pubmed">16055882</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham BL, Brusasco V, Burgos F, et al. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur Respir J. 2017;49:1600016. doi: 10.1183/13993003.00016-2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00016-2016</ArticleId><ArticleId IdType="pubmed">28049168</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2018;6:138–53. doi: 10.1016/S2213-2600(17)30433-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(17)30433-2</ArticleId><ArticleId IdType="pubmed">29154106</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W, Wu Q, Chen Z, et al. The potential indicators for pulmonary fibrosis in survivors of severe COVID-19. J Infect. 2021;82:e5–7. doi: 10.1016/j.jinf.2020.09.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.09.027</ArticleId><ArticleId IdType="pmc">PMC7521372</ArticleId><ArticleId IdType="pubmed">32998036</ArticleId></ArticleIdList></Reference><Reference><Citation>van Gassel RJJ, Bels JLM, Raafs A, et al. High Prevalence of Pulmonary Sequelae at 3 Months after Hospital Discharge in Mechanically Ventilated Survivors of COVID-19. Am J Respir Crit Care Med. 2021;203:371–4. doi: 10.1164/rccm.202010-3823LE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202010-3823LE</ArticleId><ArticleId IdType="pmc">PMC7874313</ArticleId><ArticleId IdType="pubmed">33326353</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Fan Y, Alwalid O, et al. Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia. Radiology. 2021;299:E177–86. doi: 10.1148/radiol.2021203153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2021203153</ArticleId><ArticleId IdType="pmc">PMC7841877</ArticleId><ArticleId IdType="pubmed">33497317</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulati A, Lakhani P. Interstitial lung abnormalities and pulmonary fibrosis in COVID-19 patients: a short-term follow-up case series. Clin Imaging. 2021;77:180–6. doi: 10.1016/j.clinimag.2021.03.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinimag.2021.03.030</ArticleId><ArticleId IdType="pmc">PMC8005381</ArticleId><ArticleId IdType="pubmed">33836413</ArticleId></ArticleIdList></Reference><Reference><Citation>Caruso D, Guido G, Zerunian M, et al. Post-Acute Sequelae of COVID-19 Pneumonia: Six-month Chest CT Follow-up. Radiology. 2021;301:E396–405. doi: 10.1148/radiol.2021210834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2021210834</ArticleId><ArticleId IdType="pmc">PMC8335814</ArticleId><ArticleId IdType="pubmed">34313468</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Fan Y, Alwalid O, et al. Fibrotic Interstitial Lung Abnormalities at 1-year Follow-up CT after Severe COVID-19. Radiology. 2021;301:E438–40. doi: 10.1148/radiol.2021210972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2021210972</ArticleId><ArticleId IdType="pmc">PMC8335811</ArticleId><ArticleId IdType="pubmed">34313470</ArticleId></ArticleIdList></Reference><Reference><Citation>van Raaij BFM, Stöger JL, Hinnen C, et al. Fibrotic-like abnormalities notably prevalent one year after hospitalization with COVID-19. Respir Med Res. 2022;82:100973. doi: 10.1016/j.resmer.2022.100973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resmer.2022.100973</ArticleId><ArticleId IdType="pmc">PMC9670737</ArticleId><ArticleId IdType="pubmed">36403358</ArticleId></ArticleIdList></Reference><Reference><Citation>McGroder CF, Zhang D, Choudhury MA, et al. Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere length. Thorax. 2021;76:1242–5. doi: 10.1136/thoraxjnl-2021-217031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2021-217031</ArticleId><ArticleId IdType="pmc">PMC8103561</ArticleId><ArticleId IdType="pubmed">33927016</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee I, Kim J, Yeo Y, et al. Prognostic Factors for Pulmonary Fibrosis Following Pneumonia in Patients with COVID-19: A Prospective Study. J Clin Med. 2022;11:5913. doi: 10.3390/jcm11195913.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11195913</ArticleId><ArticleId IdType="pmc">PMC9573655</ArticleId><ArticleId IdType="pubmed">36233779</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang KC, Imig JD, Kalantar-Zadeh K, et al. Kidney in the net of acute and long-haul coronavirus disease 2019: a potential role for lipid mediators in causing renal injury and fibrosis. Curr Opin Nephrol Hypertens. 2022;31:36–46. doi: 10.1097/MNH.0000000000000750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MNH.0000000000000750</ArticleId><ArticleId IdType="pubmed">34846312</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos-Murguía A, Román-Calleja BM, Toledo-Coronado IV, et al. Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19. Dig Liver Dis. 2021;53:525–33. doi: 10.1016/j.dld.2021.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2021.01.019</ArticleId><ArticleId IdType="pmc">PMC8047402</ArticleId><ArticleId IdType="pubmed">33551355</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F, Deng J, Song Y, et al. Pulmonary fibrosis in patients with COVID-19: A retrospective study. Front Cell Infect Microbiol. 2022;12:1013526. doi: 10.3389/fcimb.2022.1013526.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.1013526</ArticleId><ArticleId IdType="pmc">PMC9811255</ArticleId><ArticleId IdType="pubmed">36619759</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammadi A, Balan I, Yadav S, et al. Post-COVID-19 Pulmonary Fibrosis. Cureus. 2022;14:e22770. doi: 10.7759/cureus.22770.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.22770</ArticleId><ArticleId IdType="pmc">PMC8974316</ArticleId><ArticleId IdType="pubmed">35371880</ArticleId></ArticleIdList></Reference><Reference><Citation>Aul DR, Gates DJ, Draper DA, et al. Complications after discharge with COVID-19 infection and risk factors associated with development of post-COVID pulmonary fibrosis. Respir Med. 2021;188:106602. doi: 10.1016/j.rmed.2021.106602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2021.106602</ArticleId><ArticleId IdType="pmc">PMC8425673</ArticleId><ArticleId IdType="pubmed">34536697</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Huang DQ, Zou B, et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2021;93:1449–58. doi: 10.1002/jmv.26424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26424</ArticleId><ArticleId IdType="pmc">PMC7436673</ArticleId><ArticleId IdType="pubmed">32790106</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng D-Y, Zhou Y-Q, Zou X-L, et al. Elevated Blood Urea Nitrogen-to-Serum Albumin Ratio as a Factor That Negatively Affects the Mortality of Patients with Hospital-Acquired Pneumonia. Can J Infect Dis Med Microbiol. 2019;2019:1547405. doi: 10.1155/2019/1547405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/1547405</ArticleId><ArticleId IdType="pmc">PMC6604473</ArticleId><ArticleId IdType="pubmed">31316681</ArticleId></ArticleIdList></Reference><Reference><Citation>Beier K, Eppanapally S, Bazick HS, et al. Elevation of blood urea nitrogen is predictive of long-term mortality in critically ill patients independent of “normal” creatinine. Crit Care Med. 2011;39:305–13. doi: 10.1097/CCM.0b013e3181ffe22a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181ffe22a</ArticleId><ArticleId IdType="pmc">PMC3448784</ArticleId><ArticleId IdType="pubmed">21099426</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CL, Sullivan GD, Karalus NC, et al. Predicting early mortality in acute exacerbation of chronic obstructive pulmonary disease using the CURB65 score. Respirology. 2011;16:146–51. doi: 10.1111/j.1440-1843.2010.01866.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1843.2010.01866.x</ArticleId><ArticleId IdType="pubmed">20920140</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng A, Hu L, Wang Y, et al. Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients. Int J Antimicrob Agents. 2020;56:106110. doi: 10.1016/j.ijantimicag.2020.106110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106110</ArticleId><ArticleId IdType="pmc">PMC7377803</ArticleId><ArticleId IdType="pubmed">32712332</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W-Y, Jung S-Y, Kim J-Y, et al. ECMO is associated with decreased hospital mortality in COVID-19 ARDS. Sci Rep. 2024;14:14835. doi: 10.1038/s41598-024-64949-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-64949-x</ArticleId><ArticleId IdType="pmc">PMC11211457</ArticleId><ArticleId IdType="pubmed">38937516</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbaro RP, MacLaren G, Boonstra PS, et al. Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international Extracorporeal Life Support Organization Registry. Lancet. 2021;398:1230–8. doi: 10.1016/S0140-6736(21)01960-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01960-7</ArticleId><ArticleId IdType="pmc">PMC8480964</ArticleId><ArticleId IdType="pubmed">34599878</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassan S, Tesar T, Tisonova J, et al. Pharmacological approaches to pulmonary fibrosis following COVID-19. Front Pharmacol. 2023;14:1143158. doi: 10.3389/fphar.2023.1143158.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2023.1143158</ArticleId><ArticleId IdType="pmc">PMC10308083</ArticleId><ArticleId IdType="pubmed">37397477</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>